Cancer Immunotherapy: past, present and future

Asís Palazón, PhD

Cancer Immunotherapy: past, present and future Asís Palazón has recently joined CIC biogune as a Group leader (January 2019) supported by an ERC Starting Grant and by Ikerbasque (Basque Foundation for Science). The lab has a core focus on immuno-oncology, specifically on target discovery and drug development, with the aim of exploiting several opportunities that the hypoxia pathway in T cells offers for the treatment of cancer. Before, he was a postdoctoral researcher at the University of Cambridge, UK (Prof. Randall Johnson’s lab, 2012-2017) and then a staff scientist in the pharmaceutical industry (Medimmune, UK, 2017-2018) working on the preclinical development of cancer immunotherapies.

Next Activity

2019/12/13

Atrio 800

Seminar

Structural basis for genome-wide recognition of DNA clusters by SMAD transcription factors

Maria J. Macias, PhD

Previous Activity

2019/03/01